We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Automated Nucleic Acid Detection System Rapidly Resolves Gram-Positive Blood Cultures

By LabMedica International staff writers
Posted on 17 Jul 2013
Results obtained during a multicenter study that compared an automated diagnostic system and standard culture methods confirmed that the automated system was capable of accurately detecting most leading causes of Gram-positive bacterial blood stream infections as well as genetic markers of methicillin and vancomycin resistance directly from positive blood cultures in significantly less time than the standard procedures.

Investigators at the Medical College of Wisconsin (Milwaukee, USA) used the Nanosphere (Northbrook, IL, USA) Verigene Gram-Positive Blood Culture (BC-GP) Test to analyze 1,252 blood cultures containing Gram-positive bacteria that had been collected and tested previously at five clinical centers between April 2011 and January 2012. More...
An additional 387 contrived blood cultures containing uncommon targets (e.g., Listeria spp., S. lugdunensis, vanB-positive Enterococci) were included to fully evaluate the performance of the BC-GP test.

The Verigene BC-GP test is a multiplexed, automated nucleic acid assay for the identification of genus, species, and genetic resistance determinants for a broad panel of the most common Gram-positive blood culture isolates. The Verigene System’s unique instrumentation allows for true random access test processing, enabling on-demand testing directly from positive blood culture bottles with less than five minutes of user hands-on time per test.

The specific targets identified by the BC-GP test include Staphylococcus spp., S. aureus, S. epidermidis, S. lugdudensis, Streptococcus spp., S. pyogenes, S. agalactiae, S. anginosus group, S. pneumoniae, E. faecalis, E. faecium, and Listeria spp. as well as the mecA, vanA, and vanB genes.

BC-GP analysis was performed by laboratory technicians who had been trained by the manufacturer. A single use extraction tray was inserted into the instrument's sample processor (SP), and an aliquot of positive blood culture broth containing Gram-positive organisms was transferred to the sample well within the extraction tray. Nucleic acid was extracted from blood culture samples using magnetic bead-based extraction and reagents contained in the extraction tray. No amplification of nucleic acid was performed. Purified nucleic acid was automatically hybridized to complementary nucleic acid capture probes immobilized on a glass microarray slide within the SP. Capture probes for each BC-GP test target were present in triplicate on the array. Detection of target sequence relied on hybridization of a second, nanoparticle-conjugated, detection probe. This method allowed up to 1,000-fold greater sensitivity than fluorescent probes and required comparatively simple excitation and detection optics. Automated sample processing (nucleic acid extraction and array hybridization) in the SP required 2.5 hours. Reading of the array was conducted in the Verigene Reader following processing and took 30 to 60 seconds.

Compared to the reference culture method, the sensitivity of the Verigene BC-GP test for the bacterial species included in the test ranged from 92.6% to 100%; its specificity was 94.5%–100%. Identification of the mecA gene (a genetic marker for methicillin resistance) in cultures that contained Staphylococcus aureus or S. epidermis (Gram-positive bacteria that are often methicillin resistant) was 98.6% sensitive and 94.3% specific. Identification of the vanA gene (a genetic marker for vancomycin resistance) was 100% sensitive and specific in cultures containing Enterococcus species.

In a retrospective analysis of turn-around-time, identification of methicillin-resistant S. aureus and vancomycin-resistant Enterococcus species with the Verigene BC-GP test was about 42 hours faster than with reference methods.

The investigators concluded that, "The high sensitivity and specificity characteristics of this test, coupled with on-demand testing capability and a [two-hour turnaround time] enable reporting of both the identification and antimicrobial resistance genes of bacteria obtained from blood culture significantly faster than using routine culture methods."

The study evaluating the Verigene Gram-Positive Blood Culture Test was published in the July 2, 2013, online edition of the journal PLOS Medicine.

Related Links:
Medical College of Wisconsin
Nanosphere



New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Hematology Analyzer
Medonic M32B
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Clinical Chemistry

view channel
Image: The steps involved in the electric field-induced capture and release (EFIRM) assay (Photo courtesy of UCLA School of Dentistry)

Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation

Early detection of cancer and other serious diseases is crucial for effective treatment and improved outcomes, yet current diagnostic methods often involve invasive procedures and complex sample preparation.... Read more

Molecular Diagnostics

view channel
Image: The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is FDA-cleared for use in diagnosing Alzheimer’s (Photo courtesy of Fujirebio)

First FDA Cleared Blood Test for Alzheimer’s Diagnosis Marks Turning Point in Early Detection

Alzheimer’s disease is a progressive form of dementia that affects memory, cognition, and behavior, eventually interfering with daily activities. Early and accurate diagnosis is essential to improving... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.